Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS Currently down 187.23 (-19.33%) in today's trading session

Track congressional stock trades in Regeneron Pharmaceuticals, Inc. (REGN). Analyze trading activity from Nancy Pelosi and other members of Congress with real-time financial disclosure data, interactive price charts, and detailed transaction records.

Regeneron Pharmaceuticals, Inc. is currently trading at $781.60, positioned at 89% of its 52-week range ($476.49 – $821.11). View which politicians have recently bought or sold REGN and how their trades align with market movements.

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio in real-time with just one click on eToro.

Free asset at sign up • Eligible regions only
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$781.60
24h Change
-187.23 (-19.33%)
52 Week Range
$476.49$821.11
View on NASDAQ

Regeneron Pharmaceuticals, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for REGN

Select to highlight on chart
5 transactions
Compliance: 100%
Byron Donalds10 Apr 202524 May 2025SaleStock$1,001 - $15,000N/A (Sale Transaction)
Josh Gottheimer19 Oct 202210 Nov 2022PurchaseStock$1,001 - $15,000N/A (Price Data Unavailable)
Josh Gottheimer12 Sept 202216 Oct 2022PurchaseStock$1,001 - $15,000N/A (Price Data Unavailable)
Josh Gottheimer11 Jan 202109 Feb 2021PurchaseStock$1,001 - $15,000N/A (Price Data Unavailable)
Josh Gottheimer11 Dec 202007 Jan 2021SaleStock$1,001 - $15,000N/A (Sale Transaction)

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$81.21B

Volume

697.06K

Beta

0.40

P/E Ratio

18.84

Fundamentals

EPS

$41.49

Div. Yield

0.46%

Open

$753.74

Day Range

$753.74 — $784.00

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Leonard S. Schleifer
IPO Date
1991-04-02

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabeti...

Earnings

Next Report

Q1 2026

5 May

EPS Est.

$8.08

Rev. Est.

Days Until

57

Recent Quarters

Q4 202530 Jan
EPS$11.44
Beat 6.5%
Q3 202528 Oct
EPS$11.83
Beat 22.6%
Q2 20251 Aug
EPS$12.89
Beat 52.9%
Q1 202529 Apr
EPS$8.22
Miss 4.6%
Q4 20244 Feb
EPS$12.07
Beat 7.7%
Q3 202431 Oct
EPS$12.46
Beat 6.6%
Q2 20241 Aug
EPS$11.56
Beat 8.9%
Q1 20242 May
EPS$9.55
Miss 6.1%
Q4 20232 Feb
EPS$11.86
Beat 10.5%
Q3 20232 Nov
EPS$11.59
Beat 8.1%
Q2 20233 Aug
EPS$10.24
Beat 4.1%
Q1 20234 May
EPS$10.09
Beat 9.1%
Q4 20223 Feb
EPS$12.56
Beat 25.2%
Q3 20223 Nov
EPS$11.14
Beat 17.5%
Q2 20223 Aug
EPS$9.77
Beat 14.5%
Q1 20224 May
EPS$8.93
Miss 8.3%
Q4 20214 Feb
EPS$21.32
Beat 16.2%
Q3 20214 Nov
EPS$14.37
Beat 42.3%
Q2 20215 Aug
EPS$25.80
Beat 47.2%
Q1 20216 May
EPS$9.89
Beat 9.9%
Q4 20205 Feb
EPS$9.53
Beat 13.6%
Q3 20205 Nov
EPS$8.36
Beat 17.1%
Q2 20205 Aug
EPS$7.16
Beat 19.7%
Q1 20205 May
EPS$6.60
Beat 7.7%
Q4 20196 Feb
EPS$7.50
Beat 8.5%
Q3 20195 Nov
EPS$6.67
Beat 4.9%
Q2 20196 Aug
EPS$6.02
Beat 11.1%
Q1 20197 May
EPS$4.45
Miss 18.6%
Q4 20186 Feb
EPS$6.84
Beat 22.1%
Q3 20186 Nov
EPS$5.87
Beat 14.4%
Q2 20182 Aug
EPS$5.45
Beat 16.0%
Q1 20183 May
EPS$4.67
Beat 7.4%
Q4 20178 Feb
EPS$5.23
Beat 11.8%
Q3 20178 Nov
EPS$3.99
Beat 3.6%
Q2 20173 Aug
EPS$4.17
Beat 31.6%
Q1 20174 May
EPS$2.92
Miss 4.6%
Q4 20169 Feb
EPS$3.04
Beat 0.3%
Q3 20164 Nov
EPS$3.13
Beat 15.5%
Q2 20164 Aug
EPS$2.82
Beat 6.4%
Q1 20165 May
EPS$2.57
Beat 2.8%
Q4 20159 Feb
EPS$2.83
Miss 15.0%
Q3 20154 Nov
EPS$3.47
Beat 11.6%
Q2 20154 Aug
EPS$2.89
Beat 7.8%
Q1 20157 May
EPS$2.88
Beat 1.1%
Q4 201410 Feb
EPS$2.79
Miss 1.4%
Q3 20144 Nov
EPS$2.52
Miss 2.3%
Q2 20145 Aug
EPS$2.47
Beat 6.5%
Q1 20148 May
EPS$2.26
Beat 128.3%
Q4 201311 Feb
EPS$2.24
Beat 119.6%
Q3 20135 Nov
EPS$2.40
Beat 142.4%
Q2 20136 Aug
EPS$1.73
Beat 101.2%
Q1 20133 May
EPS$1.78
Beat 67.9%
Q4 201214 Feb
EPS$1.47
Beat 37.4%
Q3 201224 Oct
EPS$1.72
Beat 81.0%
Q2 201225 Jul
EPS$0.70
Beat 159.3%
Q1 201226 Apr
EPS$0.16
Beat 169.6%
Q4 201113 Feb
EPS$-0.54
Beat 10.0%
Q3 201127 Oct
EPS$-0.68
Beat 10.5%
Q2 201128 Jul
EPS$-0.69
Miss 68.3%
Q1 20113 May
EPS$-0.49
Miss 36.1%
Q4 201017 Feb
EPS$-0.17
Beat 46.9%
Q3 201028 Oct
EPS$-0.41
Miss 20.6%
Q2 201028 Jul
EPS$-0.31
Beat 16.2%
Q1 201029 Apr
EPS$-0.38
Beat 22.4%
Q4 200918 Feb
EPS$-0.46
Miss 35.3%
Q3 20093 Nov
EPS$-0.01
Beat 94.0%
Q2 20094 Aug
EPS$-0.19
Beat 32.1%
Q1 200930 Apr
EPS$-0.22
Beat 29.0%
Q4 200826 Feb
EPS$-0.40
Miss 33.3%
Q3 20084 Nov
EPS$-0.27
Beat 15.6%
Q2 200831 Jul
EPS$-0.23
Beat 23.3%
Q1 20081 May
EPS$-0.15
Beat 53.1%
Q4 200727 Feb
EPS$-0.19
Beat 59.6%
Q3 20076 Nov
EPS$-0.54
Miss 80.0%
Q2 20071 Aug
EPS$-0.41
Beat 4.7%
Q1 20072 May
EPS$-0.46
Beat 8.0%
Q4 20061 Mar
EPS$-0.51
Beat 0.0%
Q3 20066 Nov
EPS$-0.48
Beat 14.3%
Q2 20063 Aug
EPS$-0.41
Beat 26.8%
Q1 20063 May
EPS$-0.36
Beat 41.0%
Q4 200524 Feb
EPS$-0.53
Beat 18.5%
Q3 20053 Nov
EPS$-0.52
Beat 11.9%
Q2 20054 Aug
EPS$-0.38
Beat 25.5%
Q1 200528 Apr
EPS$-0.07
Beat 75.0%
Q4 200422 Feb
EPS$0.05
Beat 113.9%
Q3 200428 Oct
EPS$-0.20
Beat 50.0%
Q2 200426 Jul
EPS$-0.26
Beat 13.3%
Q1 200426 Apr
EPS$1.06
Beat 330.4%
Q4 200323 Feb
EPS$-0.35
Beat 34.0%
Q3 200329 Oct
EPS$-0.52
Beat 3.7%
Q2 20031 Aug
EPS$-0.58
Beat 3.3%
Q1 20035 May
EPS$-0.68
Beat 20.0%
Q4 200230 Jan
EPS$-0.81
Beat 4.7%
Q3 200231 Oct
EPS$-0.75
Beat 3.9%
Q2 200230 Jul
EPS$-0.69
Miss 7.8%
Q1 200229 Apr
EPS$-0.58
Beat 6.5%
Q4 200131 Jan
EPS$-0.65
Miss 4.8%
Q3 200122 Oct
EPS$-0.46
Beat 16.4%
Q2 200131 Jul
EPS$-0.34
Beat 34.6%
Q1 20011 May
EPS$-0.35
Beat 18.6%
Q4 200025 Jan
EPS$-0.23
Beat 32.4%
Q3 200024 Oct
EPS$-0.09
Beat 70.0%
Q2 200027 Jul
EPS$-0.08
Beat 38.5%
Q1 200028 Apr
EPS$-0.23
Miss 91.7%
Q4 19994 Feb
EPS$-0.04
Beat 81.0%
Q3 199928 Oct
EPS$-0.16
Beat 20.0%
Q2 19995 Aug
EPS$-0.25
Q2 199930 Jul
EPS$-0.25
Beat 0.0%
Q4 199829 Mar
EPS$-0.18
Q3 19985 Nov
EPS$-0.04
Q2 199814 Aug
EPS$0.07
Q1 199814 May
EPS$-0.12
Q4 199726 Mar
EPS$0.02
Q3 199714 Nov
EPS$-0.06
Q2 19971 Aug
EPS$-0.16
Beat 23.8%
Q1 19976 May
EPS$-0.23
Beat 39.5%
Q4 19965 Feb
EPS$-0.32
Beat 3.0%
Q3 199623 Oct
EPS$-0.35
Miss 2.9%
Q2 199629 Jul
EPS$-0.31
Beat 22.5%
Q1 19963 May
EPS$-0.35
Beat 2.8%
Q4 19955 Feb
EPS$-0.38
Miss 26.7%
Q3 199514 Nov
EPS$-0.32
Beat 17.9%
Q2 19951 Aug
EPS$-0.22
Beat 8.3%
Q1 19953 May
EPS$-0.22
Beat 37.1%
Q4 199413 Feb
EPS$-0.30
Beat 23.1%
Q3 199431 Oct
EPS$-0.21
Beat 41.7%
Q2 19943 Aug
EPS$-0.54
Beat 6.9%
Q1 199429 Apr
EPS$-0.57
Beat 6.6%
Q4 199328 Jan
EPS$-0.61
Beat 4.7%
Q3 199329 Oct
EPS$-0.58
Beat 6.5%
Q2 199323 Jul
EPS$-0.61
Miss 8.9%
Q1 199330 Apr
EPS$-0.61
Miss 29.8%
Q4 199225 Jan
EPS$-0.42
Beat 0.0%
Q3 199231 Dec
EPS$-0.42
Q1 199230 Jun
EPS$-0.24
Q4 199131 Mar
EPS$-0.21
Q3 199131 Dec
EPS$-0.14
Q2 199130 Sept
EPS$-0.06
Q1 199130 Jun
EPS$-0.02
Q4 199031 Mar
EPS$-0.07
Q3 199031 Dec
EPS$-0.05
Q2 199030 Sept
EPS$-0.16
Q1 199030 Jun
EPS$-0.16
Q4 198931 Mar
EPS$-0.15

3 politicians traded within 30 days

Dividends

Dividend History

20 Feb 2026
Amount $0.9400
20 Nov 2025
Amount $0.8800
18 Aug 2025
Amount $0.8800
20 May 2025
Amount $0.8800
20 Feb 2025
Amount $0.8800

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

LLY

Eli Lilly and Company

47
$1008.39+18.06 (+1.82%)
Healthcare
Held by same politician
Same sector: Healthcare
1 politician
View Stock

NVDA

NVIDIA Corporation

20
$182.65+4.77 (+2.68%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

PTSNX

PIMCO Short Term I-3

17
$9.68-0.01 (-0.10%)
Held by same politician
1 politician
View Stock
Pelosi TrackerJoin our Discord © 2026 - All rights reserved. This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.